

NMDA receptor antagonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/N2B34B6B56EDEN.html>

Date: January 2022

Pages: 120

Price: US\$ 2,000.00 (Single User License)

ID: N2B34B6B56EDEN

Abstracts

This report can be delivered to the clients within 72 hours

DelveInsight's, "NMDA Receptor Antagonists - Pipeline Insight, 2022" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in NMDA Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

NMDA Receptor Antagonists Understanding

NMDA Receptor Antagonists: Overview

The NMDA receptor is an ionotropic receptor that allows for the transfer of electrical signals between neurons in the brain and in the spinal column. N-methyl-D-aspartate receptor is a ligand of glutamate, which is the primary excitatory neurotransmitter in the human brain. The activation of NMDA receptors has been associated with hyperalgesia, neuropathic pain, and reduced functionality of opioid receptors. Molecules that block the NMDA receptor are called NMDA-receptor antagonists. N-methyl-D-aspartate receptors are also expressed across a wide spectrum of non-neuronal cells, including central and peripheral glial cells, endothelium, bone, kidney, pancreas, and others. NMDA-receptor antagonists can be used in the management of chronic pain and Alzheimer's disease. Commercially available NMDA-receptor antagonists include ketamine,

dextromethorphan, memantine, and amantadine. The opioids methadone, dextropropoxyphene, and ketobemidone are also antagonists at the NMDA receptor.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence NMDA Receptor Antagonists R&D. The therapies under development are focused on novel approaches for NMDA Receptor Antagonists.

NMDA Receptor Antagonists Emerging Drugs Chapters

This segment of the NMDA Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

NMDA Receptor Antagonists Emerging Drugs

NP-120 (Ifenprodil): Algernon Pharmaceuticals

NP-120 (Ifenprodil) is an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil also exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. NP-120 (Ifenprodil – brand name Cerocal) was initially developed by Sanofi in the 1990s in the French and Japanese markets for the treatment of circulatory disorders. This repurposed drug is under clinical evaluation for the treatment of idiopathic pulmonary fibrosis (IPF) and COVID 2019 infections.

REL 1017: Relmada Therapeutics

REL-1017 is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. The drug is currently in late-stage studies as an adjunctive treatment for MDD in adults. In April 2017, the FDA granted Fast Track designation for

REL-1017 for the adjunctive treatment of major depressive disorder.

Further product details are provided in the report.....

NMDA Receptor Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different NMDA Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on NMDA Receptor Antagonists

There are approx. 25+ key companies which are developing the NMDA Receptor Antagonists. The companies which have their NMDA Receptor Antagonists drug candidates in the most advanced stage, i.e. Phase III include, Relmada Therapeutics.

Phases

DelveInsight's report covers around 25+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

NMDA Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

NMDA Receptor Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses NMDA Receptor Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NMDA Receptor Antagonists drugs.

NMDA Receptor Antagonists Report Insights

- NMDA Receptor Antagonists Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

NMDA Receptor Antagonists Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing NMDA Receptor Antagonists drugs?

How many NMDA Receptor Antagonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for NMDA Receptor Antagonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the NMDA Receptor Antagonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for NMDA Receptor Antagonists and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Algernon Pharmaceuticals

Relmada Therapeutics

UCB

Avanir Pharmaceuticals

Axsome Therapeutics

Seelos Therapeutics

PharmaTher

Cessatech

ATAI Life Sciences

Small Pharma

Bexson Biomedical

DemeRx

Key Products

NP-120 (Ifenprodil)

REL 1017

Lacosamide

Deudextromethorphan

AXS-05

SLS-002

Ketamine microneedle patch

CT-001

PCN-101

SPL-801-B

BB-106

Ibogaine

Contents

Introduction

Executive Summary

NMDA Receptor Antagonists: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

NMDA Receptor Antagonists – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

NMDA Receptor Antagonists companies' collaborations, Licensing, Acquisition -Deal

Value Trends

NMDA Receptor Antagonists Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

REL 1017: Relmada Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II/III)

Comparative Analysis

NP-120 (Ifenprodil): Algernon Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

Comparative Analysis

Ketamine microneedle patch: PharmaTher

Product Description

Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Pre-clinical and Discovery Stage Products
Comparative Analysis
SPL-801-B: Small Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
NMDA Receptor Antagonists Key Companies
NMDA Receptor Antagonists Key Products
NMDA Receptor Antagonists- Unmet Needs
NMDA Receptor Antagonists- Market Drivers and Barriers
NMDA Receptor Antagonists- Future Perspectives and Conclusion
NMDA Receptor Antagonists Analyst Views
NMDA Receptor Antagonists Key Companies
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for NMDA Receptor Antagonists
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for NMDA Receptor Antagonists

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: NMDA receptor antagonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/N2B34B6B56EDEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N2B34B6B56EDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970